Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;83(6):912-924.
doi: 10.1111/his.15034. Epub 2023 Aug 29.

Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma

Thomas Denize  1 , Catherine B Meador  2 , Anna B Rider  1 , Maria L Ganci  1 , Jaimie L Barth  1 , Marina Kem  1 , Mari Mino-Kenudson  1 , Yin P Hung  1
Affiliations

Concordance of ASCL1, NEUROD1 and POU2F3 transcription factor-based subtype assignment in paired tumour samples from small cell lung carcinoma

Thomas Denize et al. Histopathology. 2023 Dec.

Abstract

Aims: Small cell lung carcinoma (SCLC) can be classified into transcription factor-based subtypes (ASCL1, NeuroD1, POU2F3). While in-vitro studies suggest intratumoral heterogeneity in the expression of these markers, how SCLC subtypes vary over time and among locations in patients remains unclear.

Methods and results: We searched a consecutive series of patients at our institution in 2006-22 for those with greater than one available formalin-fixed paraffin-embedded SCLC sample in multiple sites and/or time-points. Immunohistochemistry for ASCL1, NeuroD1 and POU2F3 was performed and evaluated using H-scores, with subtype assigned based on the positive marker (H-score threshold >10) with the highest H-score. The 179 samples (75, lung; 51, lymph nodes; 53, non-nodal metastases) from 84 patients (74 with two, 10 with more than two samples) included 98 (54.7%) ASCL1-dominant, 47 (26.3%) NeuroD1-dominant, 15 (8.4%) POU2F3-dominant, 17 (9.5%) triple-negative and two (1.1%) ASCL1/NeuroD1 co-dominant samples. NeuroD1-dominant subtype was enriched in non-lung locations. Subtype concordance from pairwise comparison was 71.4% overall and 89.7% after accounting for ASCL1/NeuroD1-dual expressors and technical factors including <500 cells/slide, H-score thresholds and sample decalcification. No significant difference in subtype concordance was noted with a longer time lapse or with extrathoracic versus intrathoracic samples in this cohort.

Conclusions: After accounting for technical factors, transcription factor-based subtyping was discordant among multiple SCLC samples in ~10% of patients, regardless of sample locations and time lapse. Our findings highlighted the spatiotemporal heterogeneity of SCLC in clinical samples and potential challenges, including technical and biological factors, that might limit concordance in SCLC transcription factor-based subtyping.

Keywords: ASCL1; NeuroD1; POU2F3; concordance; small cell carcinoma; spatiotemporal heterogeneity; subtype.

PubMed Disclaimer

References

    1. Beasley MB, Brambilla E, MacMahon H et al. Small cell lung carcinoma. In WHO classification of tumors series, thoracic tumors. Vol. 5. 5th ed. Lyon, France: International Agency for Research on Cancer, 2021; 139-143.
    1. Govindan R, Page N, Morgensztern D et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J. Clin. Oncol. 2006; 24; 4539-4544.
    1. Varghese AM, Zakowski MF, Yu HA et al. Small-cell lung cancers in patients who never smoked cigarettes. J. Thorac. Oncol. 2014; 9; 892-896.
    1. Lee JK, Lee J, Kim S et al. Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas. J. Clin. Oncol. 2017; 35; 3065-3074.
    1. Marcoux N, Gettinger SN, O'Kane G et al. EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes. J. Clin. Oncol. 2019; 37; 278-285.

MeSH terms

Substances

LinkOut - more resources